Tocilizumab role in reducing the complications of COVID patients
Phase 3
Active, not recruiting
- Conditions
- Pneumonia due to COVID-19B34.2
- Registration Number
- RBR-25rtydq
- Lead Sponsor
- ady Reading Hospital-MTI Peshawar
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruitment completed
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Confirmed or suspected SARS-CoV infection; Adult patient; Moderate to Critical COVID Patients
Exclusion Criteria
Known hypersensitivity to Tocilizumab or its excipients; patient below 18 years; mild cases of Confirmed or suspected SARS-CoV
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Rate of mortality in patients receiving tocilizumab in the hospital, verified by chi square test, it was observed that patients receiving invasive respiratory support were identified to higher risk of mortality than patients receiving oxygen support ( (50 vs 86, p<0.05)
- Secondary Outcome Measures
Name Time Method Secondary outcomes are not expected
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Tocilizumab's efficacy in reducing cytokine storm in B34.2 pneumonia patients?
How does Tocilizumab compare to standard-of-care treatments for severe COVID-19 pneumonia in phase III trials?
Which biomarkers correlate with Tocilizumab response in patients with cytokine release syndrome from B34.2 pneumonia?
What are the most common adverse events associated with Tocilizumab treatment in phase III trials for B34.2 pneumonia?
How do Tocilizumab's IL-6 receptor antagonism effects compare to other immunomodulators in treating severe SARS-CoV-2 pneumonia?